関連する実験動画
Updated: Sep 9, 2025

07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
538
PD-1抗体-薬物結合体およびその抗腫瘍メカニズムによるがん免疫療法の革新
Jianwei Wang1, Zeyu Chen2, Yanling Wu3
1Lab of Drug Design and Synthesis, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing 313299, China; Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Deqing 313299, China.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|August 30, 2025
まとめ
プログラムされた死-1 (PD-1) を標的とする新型抗体-薬物結合剤 (ADC) は,がん免疫療法に対する二重アプローチを提供します. これらのPD-1ADCはT細胞の枯渇を逆転させ,細胞毒物質を直接腫瘍に投与し,免疫反応を強化し,抵抗を克服します.
科学分野:
- 腫瘍学
- 免疫療法
- 薬物開発
背景:
- 抗体-薬物結合体 (ADCs) は,がん治療における有望な進歩を表しています.
- プログラムされた死亡-1 (PD-1) 阻害剤は,現代のがん免疫療法の礎石です.
- 従来のPD-1阻害剤に対する耐性は,新しい治療戦略を必要とします.
研究 の 目的:
- プログラムされた死-1 (PD-1) を標的とする抗体-薬物結合体 (ADC) を導入し,評価する.
- T細胞の枯渇を逆転させ,細胞毒性の負荷を与えるPD-1ADCの二重メカニズムを探求する.
- 既存の免疫療法に対する耐性を克服するPD-1ADCの可能性を評価する.
主な方法:
- PD-1を標的とする新しい抗体-薬物結合体 (ADC) の開発.
- 関連するがんモデルにおけるPD-1 ADCの臨床前評価
- 腫瘍の微小環境における免疫調節と直接の細胞毒性の分析
主要な成果:
- PD-1ADCは,PD-1発現細胞に選択的に結合することを示しています.
- これらの薬剤はT細胞の枯渇を逆転させ,免疫抑制細胞を排除する可能性がある.
- この二重メカニズムは,抗腫瘍免疫を強化し,従来のPD-1阻害剤で観察された耐性を治療します.
結論:
- PD- 1 ADCは,双重な作用メカニズムを持つ新種のがん免疫療法です.
- 腫瘍抗原の異質性や耐性開発などの課題については,さらなる調査が必要である.
- ADCの設計とペイロードの最適化における将来のイノベーションは,臨床の成功に不可欠です.
関連する概念動画
Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cancer Vaccines
509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509
Cytotoxic T Cells-mediated Immune Response
1.9K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.9K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K

